← Human Trials & Peer-Reviewed Studies
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
Plain-language guide to PMID 34186022 (2021): double-blind randomized controlled trial study of Tirzepatide and GIP (Gastric Inhibitory Polypeptide).
Key Facts
- PMID
- 34186022
- Journal
- Lancet (London, England)
- Year
- 2021
- Study type
- Randomized Controlled Trial
- Authors
- Rosenstock J et al. (10 authors)
- DOI
- 10.1016/S0140-6736(21)01324-6
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Tirzepatide and GIP (Gastric Inhibitory Polypeptide), published as a randomized controlled trial.
Despite advancements in care, many people with type 2 diabetes do not meet treatment goals; thus, development of new therapies is needed.
Who Took Part
By PubMed's age tags, the people studied were middle-aged adults, both men and women.
Adult participants (≥18 years) were included if they had type 2 diabetes inadequately controlled by diet and exercise alone and if they were naive to injectable diabetes therapy.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
Because people in this Tirzepatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
As a double-blind Tirzepatide study, the assignments were hidden from both participants and investigators until the end.
Some participants received a placebo instead of Tirzepatide, giving a reference point.
The researchers did a 40-week, double-blind, randomised, placebo-controlled, phase 3 trial (SURPASS-1), at 52 medical research centres and hospitals in India, Japan, Mexico, and the USA.
The primary endpoint was the mean change in glycated haemoglobin (HbA1c) from baseline at 40 weeks.
This study is registered with ClinicalTrials.gov, NCT03954834.
What Was Measured
PubMed files the paper under topics including Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Glycated Hemoglobin, Hypoglycemic Agents, India, Japan and North America.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Tirzepatide and GIP (Gastric Inhibitory Polypeptide).
The abstract goes on to report its results in about 10 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2021 (Lancet (London, England)), a journal based in England.
More context: the Tirzepatide compound page and the GIP (Gastric Inhibitory Polypeptide) compound page, all human trials.
Our Notes on the Compounds
Tirzepatide: A prescription peptide medicine that acts on both the GIP and GLP-1 receptors; Mounjaro and Zepbound contain the same active ingredient.
GIP (Gastric Inhibitory Polypeptide): A 42-amino-acid gut hormone that boosts insulin release after meals; one of the two receptors tirzepatide acts on.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.